SuperRare presyoRARE

On Monday, Jones Trading initiated coverage on Korro Bio Inc. (NASDAQ:KRRO) stock with a Buy rating and a price target of $130.00. The firm highlighted the biotech company's focus on RNA editing as a significant factor in its positive outlook. Korro Bio's leading program, KRRO-110, targets alpha-1 antitrypsin deficiency (AATD), a rare pulmonary disease that affects approximately 70,000 patients in the United States. The analyst from Jones Trading expressed confidence in the potential of Korro Bio's technology, specifically the use of ADAR to modify proteins in vivo. This approach is expected to not only address AATD but also pave the way for treatments in more common conditions such as pain, liver disease, and cardiovascular disease. In anticipation of Korro Bio's progress, Jones Trading is looking forward to initial data from the Phase 1/2a study of KRRO-110, which is expected in the second half of 2025. The firm's optimism is also supported by Korro Bio's recent partnership with Novo Nordisk (NYSE:NVO) for cardiometabolic diseases, seeing this as an indicator of possible larger deals in the future due to the pharmaceutical industry's interest in RNA editing technologies. Jones Trading's initiation of coverage with a Buy rating and a $130 price target reflects a significant endorsement of Korro Bio's prospects in the biotechnology sector. The company's innovative approach to RNA editing positions it as a notable player in the development of treatments for a range of diseases. In other recent news, Korro Bio has seen significant advancements in RNA editing technology and strategic partnerships. RBC Capital Markets raised Korro Bio's stock price target to $105, following a positive outlook on RNA editing. The company's management expressed confidence in the potential of RNA editing after evaluating recent industry developments and data from peers.

On Monday, Jones Trading initiated coverage on Korro Bio Inc. (NASDAQ:KRRO) stock with a Buy rating and a price target of $130.00. The firm highlighted the biotech company's focus on RNA editing as a significant factor in its positive outlook. Korro Bio's leading program, KRRO-110, targets alpha-1 antitrypsin deficiency (AATD), a rare pulmonary disease that affects approximately 70,000 patients in the United States. The analyst from Jones Trading expressed confidence in the potential of Korro Bio's technology, specifically the use of ADAR to modify proteins in vivo. This approach is expected to not only address AATD but also pave the way for treatments in more common conditions such as pain, liver disease, and cardiovascular disease. In anticipation of Korro Bio's progress, Jones Trading is looking forward to initial data from the Phase 1/2a study of KRRO-110, which is expected in the second half of 2025. The firm's optimism is also supported by Korro Bio's recent partnership with Novo Nordisk (NYSE:NVO) for cardiometabolic diseases, seeing this as an indicator of possible larger deals in the future due to the pharmaceutical industry's interest in RNA editing technologies. Jones Trading's initiation of coverage with a Buy rating and a $130 price target reflects a significant endorsement of Korro Bio's prospects in the biotechnology sector. The company's innovative approach to RNA editing positions it as a notable player in the development of treatments for a range of diseases. In other recent news, Korro Bio has seen significant advancements in RNA editing technology and strategic partnerships. RBC Capital Markets raised Korro Bio's stock price target to $105, following a positive outlook on RNA editing. The company's management expressed confidence in the potential of RNA editing after evaluating recent industry developments and data from peers.

Interesting. Gold up 1% today. It shrugged off a strong NFP and strong dollar. This is rare. Almost as if bitcoin traded in line. Also rare.

Which Altcoins Are Worth Watching: Exploring RIFAMPICIN and UROLITHIN A in the DeSci Space The cryptocurrency market has evolved far beyond its early days of simple digital currencies, branching out into various sectors such as finance, gaming, and most recently, DeSci (Decentralized Science). Decentralized Science uses blockchain to revolutionize how scientific research is conducted, funded, and shared. Within this emerging sector, two tokens have caught the attention of Pump Science: RIFAMPICIN and UROLITHIN A. These tokens focus on decentralized scientific research, funding, and innovation. Let’s break down what these tokens represent, their use cases, and why they should be on your radar. 1.RIFAMPICIN: Decentralizing Pharmaceutical Research RIFAMPICIN is a DeSci token that aims to revolutionize the way pharmaceutical research is conducted and funded. Named after the well-known antibiotic, the RIFAMPICIN token represents a new model for supporting drug discovery, enabling decentralized funding for research, clinical trials, and production. Why Should You Watch RIFAMPICIN? Decentralized Funding for Pharmaceutical Research: Traditional pharmaceutical research often requires massive funding from private investors, institutions, or government grants. RIFAMPICIN seeks to decentralize this process by enabling global communities to invest in and support pharmaceutical research using tokenized funding pools. This could open up research into more diverse and critical areas, such as rare diseases, that are often underfunded. Transparency and Collaboration: Blockchain technology offers a transparent and immutable ledger, which can ensure that research data, trial results, and funding allocations are publicly available and traceable. This could increase collaboration between pharmaceutical companies, research institutions, and the scientific community, reducing the inefficiencies and redundancies that often plague drug discovery. Token-Based Incentives: RIFAMPICIN creates a decentralized ecosystem where scientists, researchers, and participants in drug trials can be rewarded for their contributions with tokens. These tokens can then be used to support further research, incentivizing continuous collaboration and progress in the pharmaceutical space. Direct Patient Involvement: By utilizing RIFAMPICIN, patients and patient advocacy groups can directly fund and support the development of treatments that are important to them, potentially speeding up the process for finding cures for under-researched diseases. As decentralized science continues to grow, *RIFAMPICIN could become a key player in transforming the pharmaceutical industry, making it more open, efficient, and inclusive. 2.UROLITHIN A: Transforming Longevity Research UROLITHIN A is another DeSci token that focuses on advancing research in the field of longevity and healthy aging. Urolithin A is a natural compound found in certain foods that has been shown to improve mitochondrial function, which plays a crucial role in the aging process. The UROLITHIN A token aims to decentralize the funding and research of anti-aging therapies, enabling faster progress in understanding and developing treatments for age-related diseases. Why Should You Watch UROLITHIN A? Decentralized Anti-Aging Research: The field of longevity research is growing rapidly, with significant interest in developing therapies that slow down the aging process or improve quality of life in later years. UROLITHIN A taps into this growing interest by creating a decentralized platform for funding and conducting research in this area. By using blockchain, the project allows global investors and scientific communities to collaborate on longevity research. Scientific Transparency: Like RIFAMPICIN, UROLITHIN A uses blockchain to provide transparent and verifiable research data. This ensures that findings related to longevity research are publicly accessible, allowing other scientists to replicate experiments and build upon results, which is crucial for progress in this field. Open Access to Data: Traditional scientific research can sometimes be limited by paywalls and proprietary systems. UROLITHIN A aims to make all research data and findings open access, ensuring that advancements in longevity research are available to everyone, from researchers to the general public. Community-Driven Innovation: By tokenizing the research process, UROLITHIN A enables a community-driven approach to innovation. Investors, scientists, and even citizen scientists can participate in the research process, providing new ideas, insights, and funding for projects related to aging and longevity. With an aging global population and increasing interest in longevity, UROLITHIN A has the potential to become a leading platform for research in this field, opening up new pathways for understanding and extending the human lifespan. Why Should You Watch Both RIFAMPICIN and UROLITHIN A? 1.Real-World Scientific Applications: Unlike many speculative altcoins, RIFAMPICIN and UROLITHIN A offer real-world utility by solving critical problems in the scientific and medical research fields. These tokens provide decentralized funding models for research that could lead to breakthroughs in healthcare and aging. 2.DeSci Growth Potential: The DeSci sector is still in its early stages, but its potential to disrupt traditional science and research funding models is enormous. By decentralizing the way research is conducted and financed, RIFAMPICIN and UROLITHIN A could lead to faster scientific advancements with more transparency and accessibility. 3.Community-Driven and Transparent: Both tokens are focused on using blockchain’s core features—transparency, immutability, and decentralization—to foster global collaboration and open science. This shift could lead to more equitable and efficient research processes, ultimately benefiting the broader scientific community and society as a whole. 4.Long-Term Value: As DeSci gains momentum, tokens like RIFAMPICIN and UROLITHIN A have the potential for long-term growth. With both projects offering solutions to important challenges in the medical and longevity sectors, they are well-positioned to see increased adoption and value appreciation as the space evolves. Conclusion In the rapidly evolving world of decentralized science, RIFAMPICIN and UROLITHIN A stand out as two of the most promising projects to watch. Both tokens aim to solve real-world problems in pharmaceutical and longevity research, leveraging blockchain to create more transparent, efficient, and inclusive systems for funding and conducting scientific research. By decentralizing the research process and opening it up to global communities, these tokens could play a key role in accelerating scientific advancements, particularly in healthcare and aging. If you're looking to invest in projects that have the potential to make a meaningful impact on society while also offering strong growth potential, RIFAMPICIN and UROLITHIN A should be on your radar. $URO $RIFSOL

The Role of the CRISPR Token A key component of this partnership is the integration of NuDAO’s CRISPR token, which powers the research ecosystem. CRISPR will gain access to BIO Protocol’s research ecosystem and tools, further driving innovation.   Moreover, CRISPR token holders will have the opportunity to participate in pivotal decisions, influencing the future of decentralized science.   According to NuDAO, the collaboration will enhance CRISPR’s position within the broader DeSci network, unlocking new opportunities for growth and innovation.   The ultimate goal is to create a global, decentralized community of researchers who can collaborate without borders. The long-term vision includes the commercialization of groundbreaking biotech innovations, ranging from rare diseases to longevity research.   The partnership also aligns with BIO Protocol’s recent investment from Binance Labs, a key player in the DeFi space. Worth noting, BIO Protocol reportedly raised over $64 million through a public sale, bringing its valuation to an impressive $219 million.